miRNA-372-CDK2 panel as diagnostic marker and therapeutic target for acute myeloid leukemia

PK144730BActive Publication Date: 2026-10-05SAMIAH SHAHID ASSOC PROFESSOR +1
0 Cites 0 Cited by

Patent Information

Application Number
PK202300942
Authority / Receiving Office
PK · PK
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-12-21
Publication Date
2026-10-05
Patent Text Reader

Abstract

The present invention relates to a diagnostic panel for acute myeloid leukemia (AML), comprising miRNA-372 and the CDK2 gene. The panel leverages the differential expression levels of miRNA-372 and CDK2 to distinguish between AML and healthy individuals. In particular, the panel includes miRNA-372 selected from miRNA372-5p and miRNA-372-3p, and the CDK2 gene, identified by a specific nucleotide sequence. The panel provides a tool for the early and accurate detection of AML, offering a more sensitive and noninvasive alternative to traditional diagnostic methods. The invention also includes a diagnostic kit, comprising oligonucleotide probes specific for miRNA-372 and CDK2, enabling efficient detection of the biomarker expression levels in test samples. This diagnostic panel has significant potential for clinical applications, including the early detection and monitoring of AML progression.
Need to check novelty before this filing date? Find Prior Art